Sign In
Buy CTMX
$3.70
-0.0600 (-1.60%)
At Close: Jul 13, 2026
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 08'th Jul 2026
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:22am, Wednesday, 10'th Jun 2026
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -
CytomX Therapeutics: Cashed Up With Catalysts Ahead
11:32am, Tuesday, 26'th May 2026
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, exten
CytomX Therapeutics to Present at Upcoming June Investor Conferences
08:00am, Thursday, 21'st May 2026
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that managem
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
08:00am, Monday, 18'th May 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointm
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
10:51pm, Thursday, 07'th May 2026
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
08:11pm, Thursday, 07'th May 2026
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.27 per share a year ago.
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
04:15pm, Thursday, 07'th May 2026
- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patient
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
08:00am, Thursday, 30'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wi
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
06:28pm, Wednesday, 22'nd Apr 2026
Healthcare companies with different market caps offer different rewards and challenges.
Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)
04:10am, Friday, 17'th Apr 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the target of some unusual options trading activity on Thursday. Stock traders bought 13,090 put options on the stock. This is an increas
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
02:17am, Sunday, 05'th Apr 2026
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two busi
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
03:33am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 18.8% in the undefined quarter, according to its most recent disclosure with the Securit
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade
04:14am, Friday, 20'th Mar 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday after Barclays raised their price target on the stock from $10.00 to $16.00. The stock had previously
